An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

NCT06315283 | Completed Phase 1 FDA Drug

• 2 other identifiers: TV44749-BA-101962023-505664-11-00
• Study Type: interventional
• Target: 153
• Locations: 4 countries
• Sites: 9

Brief Summary

The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. The total duration of participation in the trial for each participant is planned to be approximately 21 weeks.

Conditions

Schizophrenia

Outcome Measures

Primary Outcomes (2)

• Area under the curve (AUC) of TV-44749

  Days 57 to 85

• AUC of oral olanzapine

  24-hour period following administration of the 7th dose

Secondary Outcomes (7)

• Number of participants with at least one treatment-emergent adverse event during treatment with TV-44749

  Days 1 to 113

• Number of participants with at least one treatment-emergent serious adverse event during treatment with TV-44749

  Days 1 to 113

• Number of participants with at least one injection site adverse event during treatment with TV-44749

  Days 1 to 113

• Maximum observed plasma drug concentration at steady state (Cmax,ss) of TV-44749

  Day 57 to Day 85

• Plasma concentration at the end of the dosing interval at steady state (Ctrough,ss) of TV-44749

  Day 85

Study Arms (2)

Oral olanzapine

ACTIVE COMPARATOR

Drug: Oral olanzapine

TV-44749

EXPERIMENTAL

Drug: TV-44749

Interventions

TV-44749 DRUG

Administered subcutaneously (sc)

Also known as: Olanzapine

TV-44749

Oral olanzapine DRUG

Administered orally

Also known as: ZYPREXA®

Oral olanzapine

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Agree to maintain current smoking or nonsmoking status at the time informed consent is obtained and throughout the trial until completion of the EOT or ET visit (ie, nonsmoking participants must agree not to start smoking and participants who smoke will be excluded if they plan to discontinue smoking during the trial period).
• Have a current confirmed diagnosis of schizophrenia according to an evaluation by the Investigator, as defined by the DSM-5 (American Psychiatric Association 2013a).
• Women may be included only if they have a negative serum beta human chorionic gonadotropin (HCG) test result at screening; they are surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (postmenopausal status will be confirmed by a follicle-stimulating hormone screen according to the clinical laboratory standard value) for at least 1 year; or they are practicing a highly effective method of birth control and not planning pregnancy for at least 30 days before the trial, for the duration of the trial, and for 70 days after the last dose administration, if they are sexually active and of childbearing potential.
• Men must be sterile; or if they are potentially of reproductive competence and have sexual relationship with female partners of childbearing potential, they must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 70 days after the last dose administration.
• NOTE- Additional criteria apply, please contact the investigator for more information

You may not qualify if:

• History or known risk of narrow-angle glaucoma.
• History or a complication of diabetes (hemoglobin A1c 6.5% or above and/or fasting plasma glucose 126 mg/dL or above).
• Evidence of significant hepatic disorder.
• The participant is a pregnant or lactating woman or plans to become pregnant during the trial or within 70 days after the last dose administration.
• Known hypersensitivity or idiosyncratic reaction to olanzapine (or unable to tolerate oral olanzapine dose) or any of the excipients of TV-44749 in any formulation, their related compounds, or to any metabolites, or any compound listed as being present in TV-44749 or oral olanzapine.
• Presence of excessive pigment, bruises, scars, or tattoos around the potential injection area.
• Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, long QT syndrome, personal history of syncope, or history of uncontrolled high blood pressure. Participants with history of high blood pressure who no longer require treatment or participants who are treated with antihypertensive medications and whose blood pressure is currently well-controlled, may be enrolled.
• Substance use disorder criteria for alcohol, drug, or any other substance dependence (with the exception of nicotine or caffeine) have been met within the past 12 months prior to screening as defined by the DSM-5 (American Psychiatric Association 2013b).
• A current clinically significant DSM-5 diagnosis other than schizophrenia.
• NOTE- Additional criteria apply, please contact the investigator for more information

Sponsors & Collaborators

• Teva Branded Pharmaceutical Products R&D LLC: lead

Study Sites (9)

Teva Investigational Site 15739

Los Alamitos, California, 90720, United States

Location

Teva Investigational Site 15740

Torrance, California, 90504, United States

Location

Teva Investigational Site 15738

Hollywood, Florida, 33024, United States

Location

Teva Investigational Site 15741

Atlanta, Georgia, 30331, United States

Location

Teva Investigational Site 15742

Decatur, Georgia, 30030, United States

Location

Teva Investigational Site 15737

Marlton, New Jersey, 08053, United States

Location

Teva Investigational Site 60053

Zagreb, 10090, Croatia

Location

Teva Investigational Site 31326

Zamora, 49021, Spain

Location

Teva Investigational Site 34310

Surrey, KT22 7AD, United Kingdom

Location

MeSH Terms

Conditions

Schizophrenia

Interventions

Olanzapine

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Teva Medical Expert, MD

  Teva Branded Pharmaceutical Products R&D LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 11, 2024
• First Posted: March 18, 2024
• Study Start: March 20, 2024
• Primary Completion: August 14, 2025
• Study Completion: September 4, 2025
• Last Updated: January 14, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share

Locations

ES (1); GB (1); US (6); CR (1)